Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andra Cīrule
Observed names:
A. Cirule,
Andra Cirule
Institution:
Riga East University Hospital
Observed institutions:
National Health Service,
The Royal Free Hospital,
Public Health England,
National Institute for Health and Care Research,
Riga East University Hospital,
KNCV TB Plus,
University College London,
Imperial College London,
Medical Research Council,
University of Latvia
show all 10
OpenAlex ID:
A5032835548
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
2018
·
Nafees Ahmad
, Shama D Ahuja
, et al.
·
The Lancet
·
728
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
2012
·
Vija Skripconoka
, Manfred Danilovits
, et al.
·
European Respiratory Journal
·
364
PDF
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
2019
·
Florian von Groote-Bidlingmaier
, Ramonde Patientia
, et al.
·
The Lancet Respiratory Medicine
·
180
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance
2015
·
J. Peter Cegielski
, Ekaterina Kurbatova
, et al.
·
Clinical Infectious Diseases
·
110
PDF
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update
2018
·
Giovanni Battista Migliori
, Giovanni Sotgiu
, et al.
·
European Respiratory Journal
·
102
PDF
Delamanid for Extensively Drug-Resistant Tuberculosis
2015
·
Rajesh Gupta
, Mengqui Gao
, et al.
·
New England Journal of Medicine
·
60
PDF
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
2016
·
Helen R. Stagg
, Peter J. White
, et al.
·
Emerging infectious diseases
·
31
PDF
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships
2024
·
Viktorija Ulanova
, Agnija Kivrane
, et al.
·
Frontiers in Pharmacology
·
24
PDF
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring
2021
·
Agnija Kivrane
, Solveiga Grinberga
, et al.
·
Journal of Chromatography B
·
14
PDF
Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study
2015
·
Helen R. Stagg
, James Brown
, et al.
·
PLoS ONE
·
13
PDF
Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients
2016
·
Viktorija Igumnova
, Valentina Capligina
, et al.
·
Journal of Infection and Chemotherapy
·
11
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis
2015
·
Thelma Tupasi
, Rajesh Gupta
, et al.
·
Bulletin of the World Health Organization
·
11
PDF
The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia
2013
·
Thaddeus L Miller
, Andra Cirule
, et al.
·
Cost Effectiveness and Resource Allocation
·
7
PDF
TB management in the European Union/European Economic Area: a multi‐centre survey
2021
·
G. Sotgiu
, S. Rosales-Klintz
, et al.
·
The International Journal of Tuberculosis and Lung Disease
·
6
Late Breaking Abstract - Variations in current clinical practices in nontuberculous mycobacterial lung disease (NTM-LD) management across European countries: results from a multinational expert survey
2026
·
Vaiva Kumpauskaitė
, Ágnes Bakos
, et al.
·
European Respiratory Journal
Late Breaking Abstract - Variability in tuberculosis diagnostic and treatment approaches across European countries: results from a multinational expert survey
2026
·
Vaiva Kumpauskaitė
, Ágnes Bakos
, et al.
·
European Respiratory Journal
Fluctuations in circulating cell-free mitochondrial and nuclear DNA copy numbers in blood plasma after anti-tuberculosis drug intake in patients with drug-susceptible tuberculosis
2025
·
Lauma Freimane
, Agnija Kivrāne
, et al.
·
Tuberculosis
REKOMENDĀCIJAS par SARS-CoV-2 infekcijas un COVID-19 epidemioloģiju, diagnostiku, klīniskajām norisēm un komplikācijām
2021
·
Ludmila Vīksna
, Ieva Tolmane
, et al.
Management of tuberculosis in the European Union: a multicentre audit
2018
·
Senia Rosales-Klintz
, Lia D’ambrosio
, et al.
·
European Respiratory Journal
Show more works
View as search
Works count:
19
Citation count:
1,661
H-index:
11
I10-index:
12
Year
Topic
Type